menu_open Columnists
We use cookies to provide some features and experiences in QOSHE

More information  .  Close

The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up

15 5
04.03.2025
Wegovy, Zepbound, Saxenda, and other GLP-1 or GIP medications are needlessly out of reach for many Americans.

© Fortune